Brii Biosciences Reports Major Developments and 2025 Financial Results

Brii Biosciences: A Year of Progress in Battling HBV

In the competitive biotechnology landscape, Brii Biosciences Limited has taken significant strides towards improving health outcomes for patients battling chronic hepatitis B virus (HBV) infections. The company, known as Brii Bio and trading under the stock code 2137.HK, recently provided detailed updates on its corporate strategy and reported its full-year financial results for 2025.

Strategic Advancements in HBV Treatments

In a decisive year, Brii Bio demonstrated its commitment to addressing the unmet medical needs of chronic HBV patients through innovative treatment strategies. The company reported promising findings from its ENSURE Phase 2b study, presented at prominent liver disease conferences such as the American Association for the Study of Liver Diseases (AASLD) and published in Nature Medicine. Early results indicated that the investigational therapy BRII-179 may enhance functional cure rates across diverse patient populations. Utilizing insights gleaned from these studies, Brii Bio has modified protocols for its ENHANCE study to assess a newer triple combination treatment aimed at optimizing treatment duration without compromising efficacy. Both ENRICH and ENHANCE studies are now completely enrolled, with results expected to be disclosed in the latter half of 2026.

Financial Standing and Management Adjustments

As of December 31, 2025, Brii Bio's strong financial management practices have led to a solid cash position of approximately USD 276.1 million. This financial foundation was reached while making strategic adjustments to its operational structures and executive compensation frameworks, aiming to better align management incentives with long-term performance and shareholder interests. The company witnessed an overall revenue of RMB 18.6 million for the year, attributed primarily to intellectual property agreements.

Despite a net loss of RMB 224.1 million, a notable reduction in losses was achieved compared to the previous year, showcasing efficient cost control measures and focused investment strategies.

Innovation in Drug Discovery

Further enhancing its research capabilities, Brii Bio expanded its discovery efforts under the new leadership of Chief Scientific Officer Dr. Brian Johns. The company now boasts enhanced in-house discovery capabilities across its labs in Beijing and Shanghai, supported by a skilled team ready to leverage China’s robust drug development ecosystem. Brii Bio aims to expedite the clinical translation of therapeutic insights, efficiently selecting viable drug targets while advancing early-stage programs through crucial milestones.

In December, Brii Bio reinforced its commitment to innovation by announcing a collaboration with OpenBench to tap into artificial intelligence technologies for speeding up its discovery initiatives.

Future Outlook and Strategic Intent

As the company navigates through 2026, it remains steadfast in its mission to innovate and execute its strategic plan, focusing on achieving a functional cure for chronic HBV infection. Clinically relevant data from the ENRICH and ENHANCE studies will guide future registrations and market strategies. The approach is firmly grounded in a balanced strategy, acknowledging near-term goals while maintaining a robust long-term vision for pipeline growth and product development. Brii Bio’s focus on disciplined execution, underpinned by its strong cash reserves, positions the company well to become a key player in the biotechnology field.

With upcoming conference calls and continued transparency, Brii Biosciences invites stakeholders to stay engaged with its progress towards novel therapeutics aimed at transforming patient care in the fight against hepatitis B.